Collaboration that brings change
We collaborate with reputed organisations with the vision to bring revolution in the healthcare sector. Their firm belief in Cadila’s philosophy has helped us together create a valuable impact in the society.
In 2006, Cadila Pharmaceuticals entered into a joint venture with Apollo Hospitals Group to manage Apollo Hospitals, Ahmedabad. Over the last decade, it has been recognized as a centre of excellence and has emerged as a trusted destination for the patients in the region.
In 2008, Cadila Pharmaceuticals formed a JV with StemCyte Inc. USA, organization dedicated to the collection, processing, testing and storage of both – private and public umbilical cord blood units and its therapeutic applications.
In 2009, Cadila Pharmaceuticals acquired a significant stake in Novavax Inc., USA, a clinical-stage biopharmaceutical company to form a joint venture, CPL Biologicals, which develops and produces vaccines based on virus-like-particle (VLP) methodology.
In 2016, Cadila Pharmaceuticals entered into a collaboration agreement with Oncology Venture Sweden AB (OV) for novel Liposomal formulation of cisplatin treatment for treating solid tumours.
Under a research collaboration agreement with Lipdor, Cadila Pharmaceuticals has initiated a phase 3 clinical trial for the development of differentiated Calcipotrial formulation ( Spray) for the treatment of Psoriasis.
In 2017, Cadila Pharmaceuticals entered into a collaboration with Aplagon Oy, Finland for development and commercialization of heparin proteoglycan mimetic for use in certain vascular surgeries.